NPI: 1891003323 · MIRAMAR, FL 33027 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 09/17/2010
Authorized official WEY, SAMUEL controls 20+ related entities in our dataset. Read more
| Authorized Official | WEY, SAMUEL (VP, LICENSURE & CERTIFICATION) |
| NPI Enumeration Date | 09/17/2010 |
Other providers sharing the same authorized official: WEY, SAMUEL
| Provider | City | State | Total Paid |
|---|---|---|---|
| DVA HEALTHCARE RENAL CARE INC | NORTH HOLLYWOOD | CA | $16.47M |
| DVA HEALTHCARE RENAL CARE INC | DELANO | CA | $16.43M |
| DVA RENAL HEALTHCARE INC | LOS ANGELES | CA | $15.51M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $14.93M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.67M |
| DVA RENAL HEALTHCARE INC | OAKLAND | CA | $13.42M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.25M |
| DVA HEALTHCARE RENAL CARE INC | YUMA | AZ | $12.88M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $12.77M |
| DVA RENAL HEALTHCARE INC | FULLERTON | CA | $12.19M |
| DVA HEALTHCARE RENAL CARE INC | POMONA | CA | $11.96M |
| DVA RENAL HEALTHCARE INC | ANAHEIM | CA | $11.32M |
| DVA RENAL HEALTHCARE INC | ESCONDIDO | CA | $10.94M |
| DVA HEALTHCARE RENAL CARE INC | COSTA MESA | CA | $10.08M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $9.46M |
| DVA RENAL HEALTHCARE INC | VISALIA | CA | $9.22M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $8.83M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $8.56M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $7.78M |
| DVA RENAL HEALTHCARE INC | PALM SPRINGS | CA | $7.48M |
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 6,936 | $1.89M |
| 2019 | 11,928 | $2.71M |
| 2020 | 7,328 | $1.92M |
| 2021 | 1,344 | $189K |
| 2023 | 136 | $54K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 8,771 | 449 | $2.39M |
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 7,925 | 539 | $1.89M |
| J1270 | Injection, doxercalciferol, 1 mcg | 5,854 | 386 | $1.20M |
| A4657 | Syringe, with or without needle, each | 851 | 526 | $329K |
| J1756 | Injection, iron sucrose, 1 mg | 1,597 | 310 | $318K |
| 85041 | 546 | 384 | $128K | |
| 85048 | 447 | 326 | $116K | |
| 83970 | 407 | 213 | $103K | |
| 83550 | 406 | 278 | $86K | |
| 83540 | 407 | 279 | $86K | |
| 82728 | 212 | 145 | $48K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 161 | 112 | $39K |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 50 | 27 | $18K |
| 82108 | 38 | 27 | $13K |